533 related articles for article (PubMed ID: 33866190)
21. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis.
He X; Sun L; Huo Y; Shao M; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
[TBL] [Abstract][Full Text] [Related]
23. Prediction of the axillary lymph-node metastatic burden of breast cancer by
Li Y; Han D; Shen C
BMC Cancer; 2024 Jun; 24(1):704. PubMed ID: 38849770
[TBL] [Abstract][Full Text] [Related]
24. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
25. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
26. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
27. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
28. Assessing
Sarikaya I; Sarikaya A
J Nucl Med Technol; 2019 Jun; 47(2):149-153. PubMed ID: 30413593
[No Abstract] [Full Text] [Related]
29. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
[TBL] [Abstract][Full Text] [Related]
30. FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study.
Eifer M; Pinian H; Klang E; Alhoubani Y; Kanana N; Tau N; Davidson T; Konen E; Catalano OA; Eshet Y; Domachevsky L
Eur Radiol; 2022 Sep; 32(9):5921-5929. PubMed ID: 35385985
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic ability of
Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
[TBL] [Abstract][Full Text] [Related]
33. A prospective comparative study of ultrasonography, contrast-enhanced MRI and 18F-FDG PET/CT for preoperative detection of axillary lymph node metastasis in breast cancer patients.
Guney IB; Dalci K; Teke ZT; Kucuker KA
Ann Ital Chir; 2020; 91():458-464. PubMed ID: 32213685
[TBL] [Abstract][Full Text] [Related]
34. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
[TBL] [Abstract][Full Text] [Related]
35. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
36. The roles of
Nakano Y; Noguchi M; Yokoi-Noguchi M; Ohno Y; Morioka E; Kosaka T; Takahashi T; Minato H
Breast Cancer; 2017 Jan; 24(1):121-127. PubMed ID: 27015862
[TBL] [Abstract][Full Text] [Related]
37. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
38. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer.
Zornoza G; Garcia-Velloso MJ; Sola J; Regueira FM; Pina L; Beorlegui C
Eur J Surg Oncol; 2004 Feb; 30(1):15-9. PubMed ID: 14736517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]